Pharmaron Beijing : Reply Slip for the First H Shares Class Meeting of 2021
April 28, 2021 at 06:30 am EDT
Share
Pharmaron Beijing Co., Ltd.*
康龍化成(北京) 新藥技術 股份有限 公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 3759)
Reply Slip for the First H Shares Class Meeting of 2021
To: Pharmaron Beijing Co., Ltd.* (康龍化成 (北京) 新藥技術股份有限公司) (the "Company")
I/We(Note 1) (name)
of
(Note 1)
(address as shown in the register of members) and (telephone number(Note 2)
)
being the registered holder(s) of
(Note 3) H Shares of RMB1.00 each in
the share capital of the Company hereby inform the Company that I/we intend to attend, in person or by proxy, the first H Shares Class Meeting of 2021 (the "H Shares Class Meeting") of the Company after the conclusion of the Annual General Meeting of 2020 to be held at 6 Tai-He Road, Economic Technological Development Area, Beijing, the PRC on Friday, May 28, 2021 at 2 p.m.
Date:
Signature of Shareholder(s)(Note 4):
Notes:
Please insert the full name(s) and address(es) as registered in the register of members of the Company in BLOCK LETTERS.
For verification purpose, please insert your telephone number via which you can be contacted.
Please insert the number of shares of the Company registered in your name(s).
If you intend to attend the AGM in person or by proxy, this completed and signed reply slip should be delivered by hand or by post to the Company's H Shares Registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong no later than Monday, May 24, 2021. In order to be qualified to attend and vote at the AGM, all transfer documents accompanied by the relevant share certificate(s) must be delivered to the Company's H Shares Registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, at Shops 1712-1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong for registration no later than 4:30 p.m. on Monday, May 24, 2021.
For identification purposes only
Attachments
Original document
Permalink
Disclaimer
Pharmaron Beijing Co. Ltd. published this content on 28 April 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 April 2021 10:29:34 UTC.
Pharmaron Beijing Co. is specialised in the research, development and manufacturing of small molecule drugs, cell therapies and gene therapies. Net sales break down by activity as follows:
- laboratory services (61.3%);
- development and production of chemical processes and formulations (23.5%);
- clinical research services (12.8%);
- other (2.4%);
Net sales are distributed geographically as follows: China (17.1%), Asia (2.6%), North America (64.2%), Europe (15.6%) and other (0.5%).
PHARMARON BEIJING CO., LTD. 
